Alcon (ALC) closed at $72.46 on November 11, 2026, down 2.2% from the previous close, on volume of 4,129,741 shares (30-day average 1,884,692).
Data as of November 11, 2026.
11-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 10, 2026 | Seagull Ratio With Put Spread | 20-Nov-2667.5 P : 70 P : 80[2x] C | 3,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
Barclays Sticks to Its Hold Rating for Alcon (ALC)
TipRanks (Thu, 12-Nov 1:55 AM ET)
TipRanks (Thu, 12-Nov 1:50 AM ET)
Alcon Earnings Call Shows Growth Amid Rising Headwinds
TipRanks (Wed, 11-Nov 7:04 PM ET)
Biggest stock movers Wednesday: CRWV, RGTI, LWLG, and more
Seeking Alpha News (Wed, 11-Nov 10:14 AM ET)
Biggest stock movers Wednesday: CRWV, RGTI, and more
Seeking Alpha News (Wed, 11-Nov 5:01 AM ET)
Alcon leans on equipment launches and dry-eye demand as Q3 core EPS reaches $0.91
Market Chameleon (Tue, 10-Nov 12:48 PM ET)
Alcon beats on bottom line but tightens 2026 guidance
Seeking Alpha News (Tue, 10-Nov 5:35 PM ET)
Alcon Reports Third-Quarter Results, Cites Neurotech Acquisition
TipRanks (Tue, 10-Nov 5:04 PM ET)
Alcon Non-GAAP EPS of $0.91 beats by $0.02, revenue of $2.7B misses by $40M
Seeking Alpha News (Tue, 10-Nov 4:33 PM ET)
Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth
Business Wire (Tue, 10-Nov 4:30 PM ET)
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Alcon trades on the NYSE stock market under the symbol ALC.
As of November 11, 2026, ALC stock price declined to $72.46 with 4,129,741 million shares trading.
ALC has a beta of 0.27, meaning it tends to be less sensitive to market movements. ALC has a correlation of 0.01 to the broad based SPY ETF.
ALC has a market cap of $35.84 billion. This is considered a Large Cap stock.
Last quarter Alcon reported $3 billion in Revenue and $.91 earnings per share. This fell short of revenue expectation by $-23 million and exceeded earnings estimates by $.02.
In the last 3 years, ALC traded as high as $101.10 and as low as $61.84.
The top ETF exchange traded funds that ALC belongs to (by Net Assets): EQTY, DFIV, DFAI, DFIC, DFAX.
ALC has underperformed the market in the last year with a return of -2.2%, while the SPY ETF gained +12.6%. In the last 3 month period, ALC fell short of the market, returning -1.6%, while SPY returned -1.5%. However, in the most recent 2 weeks ALC has outperformed the stock market by returning +4.4%, while SPY returned -1.3%.
ALC support price is $72.61 and resistance is $75.51 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALC shares will trade within this expected range on the day.
